Académique Documents
Professionnel Documents
Culture Documents
PII: S0925-4439(17)30412-X
DOI: doi:10.1016/j.bbadis.2017.10.035
Reference: BBADIS 64947
To appear in:
Received date: 28 July 2017
Revised date: 9 October 2017
Accepted date: 27 October 2017
Please cite this article as: U. Varma, P. Koutsifeli, V.L. Benson, K.M. Mellor, L.M.D.
Delbridge , Molecular mechanisms of cardiac pathology in diabetes – Experimental
insights. The address for the corresponding author was captured as affiliation for all
authors. Please check if appropriate. Bbadis(2017), doi:10.1016/j.bbadis.2017.10.035
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
ACCEPTED MANUSCRIPT
Varma U,2 Koutsifeli P,1,2 Benson VL,1 Mellor KM,*1,2,3 Delbridge LMD*2
1. Department of Physiology, University of Auckland, New Zealand
2. Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia
3. Auckland Bioengineering Institute, University of Auckland, New Zealand
PT
RI
Word count: 5112
Figures: 2
SC
Tables: 1
References: 200 NU
Keywords: diabetes, heart, metabolism, autophagy, oxidative stress
MA
E D
PT
CE
AC
Corresponding Author:
Prof LMD Delbridge
Department of Physiology
University of Melbourne
Parkville, Victoria
Australia 3010
lmd@unimelb.edu.au
Ph.: +61 3 83445853
1
ACCEPTED MANUSCRIPT
ABSTRACT
artery disease and hypertension. Diminished glucose uptake due to impaired insulin signaling and
decreased expression of glucose transporters is associated with a shift towards increased reliance on
fatty acid oxidation and reduced cardiac efficiency in diabetic hearts. The cardiac metabolic profile
in diabetes is influenced by disturbances in circulating glucose, insulin and fatty acids, and
PT
alterations in cardiomyocyte signaling. In this review, we focus on recent preclinical advances in
RI
cardiomyocyte insulin signaling intermediates has demonstrated that partial cardiac functional
SC
rescue can be achieved by upregulation of the insulin signaling pathway in diabetic hearts.
NU
Inconsistent findings have been reported relating to the role of cardiac AMPK and β-adrenergic
signaling in diabetes, and systemic administration of agents targeting these pathways appear to elicit
MA
some cardiac benefit, but whether these effects are related to direct cardiac actions is uncertain.
Overload of cardiomyocyte fuel storage is evident in the diabetic heart, with accumulation of
D
glycogen and lipid droplets. Cardiac metabolic dysregulation in diabetes has been linked with
E
oxidative stress and autophagy disturbance, which may lead to cell death induction, fibrotic
PT
‘backfill’ and cardiac dysfunction. This review examines the weight of evidence relating to the
CE
signaling pathways. Areas of uncertainty in the field are highlighted and important knowledge gaps
AC
2
ACCEPTED MANUSCRIPT
1. Introduction
Diabetic patients have a high risk of cardiovascular disease and mortality. A distinct
cardiomyopathy has been identified in patients with type 1 and type 2 diabetes (T1D, T2D),
characterized by cardiac dysfunction, fibrosis, oxidative stress and metabolic disturbance. Although
PT
hypertension [1-4]. Cardiac outcomes are influenced by diabetic systemic insult including
RI
altered cardiomyocyte molecular signaling and metabolism [5]. Additionally, volume-loading from
SC
obesity can elicit significant effects on cardiac structural remodeling, with subsequent functional
NU
disturbance.
MA
50% of asymptomatic diabetic patients [6-8], and linked to an increased risk of heart failure and
mortality, independent of systolic functional decline [9]. Impaired heart relaxation involves
E D
increased ventricular wall stiffness and abnormal cardiac filling [10, 11]. The early occurrence of
PT
diastolic dysfunction in asymptomatic diabetic patients is evident even in patients with normal
blood pressure, no vascular complications and normal contractility during systole [7, 12, 13].
CE
suggests that glycemic status is not necessarily predictive of early cardiac functional decline [14].
Treatment options targeting diastolic dysfunction are limited and understanding the molecular basis
Clinically, diabetic patients exhibit worse outcomes post-ischemia, with a higher incidence of
post-ischemic heart failure despite smaller infarct size, and are less responsive to the protective
effects of ischemic preconditioning [15-17]. Experimental studies with diabetic rodent models have
progression to heart failure [18-21]. Further work is required to elucidate the interaction between
diabetes and ischemic events, with particular focus on aligning the animal models with clinical
At the molecular level, the energy stress associated with diabetes has been shown to induce
alterations in myocardial substrate and energy metabolism [22]. Increased free fatty acids, oxidative
PT
stress and impaired protein clearance have been implicated in activating the endoplasmic reticulum
RI
stress response, linked with activation of autophagy and apoptotic cell death in the diabetic heart
SC
(reviewed in [23]). High extracellular glucose has been linked to formation of cross-linking
may provide a novel route of cellular damage in diabetic cardiomyopathy [24-26]. Glucose-
MA
mediated post-translational modifications have been well-described in diabetes, in the heart and
other tissues. O-GlcNAcylation of key Ca2+ handling proteins and signaling kinases has been shown
D
to play an important role in mediating cardiac dysfunction in diabetes (reviewed in [24, 27]). Ca2+
E
PT
SERCA2-mediated Ca2+ removal from the cytosol during diastole, changes in myofilament Ca2+
CE
sensitivity, and heightened ryanodine receptor-mediated Ca2+ leak from the sarcoplasmic reticulum
miRNAs has recently received attention for contributing to changes in expression of genes involved
in diabetic cardiomyopathy (reviewed in [30]). An understanding of the key miRNAs and their
targets is emerging and may open up new therapeutic opportunities in the field.
The focus of this review is on the molecular mechanisms of diabetic cardiomyopathy, with
pathways, accumulation of fuel stores (glycogen and lipid droplets), oxidative stress, and autophagy
4
ACCEPTED MANUSCRIPT
disturbance. We highlight areas of uncertainty in the field and identify important knowledge gaps
Adult cardiomyocytes preferentially use fatty acid oxidation for ATP production, with a smaller
PT
contribution from glucose metabolism (up to 40%) [31]. Sarcolemmal glucose uptake is primarily
RI
transporters. Decreased expression of GLUT1 and GLUT4, and reduced insulin-stimulated GLUT4
SC
translocation to the sarcolemma, are associated with decreased glucose uptake in both T1D and
T2D rodent hearts [32, 33]. Sodium-glucose co-transporters (SGLTs) are upregulated in the kidney
NU
and intestinal tissue of human diabetic patients and rodent diabetic models, facilitating glucose
MA
absorption [34]. Specifically, SGLT1 is increased in hearts of T2D patients and obese insulin
resistant mice (ob/ob), but decreased in T1D mice [35]. Cardiac SGLT1 expression is increased
with exposure to leptin [35], and upregulation of SGLT1 in T2D may provide an alternate route for
E D
glucose uptake when GLUT1 and GLUT4 are downregulated. Systemic inhibition of SGLT1 and/or
PT
SGLT2 has been advanced as an effective anti-hyperglycemic therapy (reviewed in [34]) and
multiple clinical trials are underway investigating the cardiac therapeutic potential of SGLT1
CE
cardiac expression of both GLUT1 and GLUT4 and improves cardiac function [36], suggesting that
GLUT downregulation may be linked to HDAC regulation and constitutes a central component of
diabetic cardiomyopathy.
Transporters for galactose (GLUT1,3,8,11) and fructose (GLUT5,8,11) are also expressed in
cardiomyocytes and may provide alternative fuel sources in energy stress settings [37, 38]. In
indicating that cardiomyocytes have the capacity to transport and utilize fructose [39]. Cardiac
5
ACCEPTED MANUSCRIPT
fructose content is increased in diabetes [40, 41] and may influence protein glycation damage and
the sorbitol pathway and/or endogenous fructose exposure from dietary sources. Understanding the
nuances of alternative fuel sources in the diabetic heart may provide new opportunities for
intervention.
Coincident with impaired glucose uptake, reduced glucose oxidation is a common observation in
PT
diabetic cardiomyocytes [43], associated with a shift towards increased reliance on fatty acid
RI
oxidation [22] (Figure 2). Additionally, increased fatty acid oxidation (driven by increased fatty
SC
acid uptake) might further suppress glucose oxidation via the Randle cycle [44]. In genetic mouse
models of obesity (ob/ob) and T2D (db/db), decreased glucose oxidation is observed by 4 weeks of
NU
age, associated with an increase in fatty acid oxidation and reduced cardiac efficiency, preceding
hyperglycemia [43]. Interventions to upregulate glucose oxidation, eg. via dichloroacetic acid-
MA
induced increased pyruvate dehydrogenase activity, have been shown to improve cardiac function
in both T2D (high fat diet) and T1D (STZ) rats [45, 46]. Similarly, rosiglitazone-induced PPAR-γ
D
activation in db/db mice improved cardiac efficiency associated with increased glucose oxidation
E
PT
and decreased fatty acid oxidation [47]. Together, these findings suggest that normalization of the
metabolic profile in the diabetic heart may be an important target for ameliorating cardiac function
CE
in diabetes.
AC
Given that de novo synthesis of fatty acids in the heart is limited, intracellular fatty acid availability
is reliant on circulating levels of fatty acids, uptake kinetics, and intracellular lipid depots [48]. An
increase in circulating fatty acids has been observed clinically and in T2D rodent models, associated
with impaired glucose tolerance and insulin sensitivity in muscle tissue [49]. Fatty acyl-CoA-
mediated inhibition of insulin receptor substrate signaling pathways, hexokinase inhibition and
activation stimulates fatty acid transport while suppressing glucose utilization, further promoting
6
ACCEPTED MANUSCRIPT
the shift towards fatty acid oxidation [50]. High fat-fed mice with global PPAR-α gene deletion
exhibit improved insulin sensitivity compared to their wildtype counterparts. Cardiac outcomes
were not investigated in this study [51]. In contrast, db/db mice with long term exposure to a PPAR-
α agonist exhibit enhanced cardiac glucose uptake and utilization associated with a normalization of
blood glucose and insulin, but stabilization of the cardiac metabolic profile in this setting does not
lead to functional improvement [52, 53]. HDACs may also play an important role via PPARα-
PT
mediated regulation of glucose and lipid homeostasis. HDAC inhibitors have gained attention as a
promising therapeutic intervention to improve systemic insulin resistance and glucose handling
RI
[54], and an understanding of their role in the diabetic heart is emerging. Streptozotocin (STZ)-
SC
induced T1D rats treated with HDAC inhibitor, MPT0E104, exhibit improved in vivo cardiac
function and electrocardiogram profile linked with restored cardiac expression of PPARα [55].
NU
Whether these effects are secondary to the observed improvement in systemic glucose and lipid
MA
profile, or mediated by intrinsic cardiomyocyte mechanisms is not yet clear, and investigation into
Collectively, the metabolic adaptations in the diabetic heart appear to have a detrimental impact on
E
PT
cardiac efficiency and function and may be attributed to changes in circulating glucose, insulin and
fatty acids. Advanced knowledge of the complex signaling networks connecting glucose utilization
CE
and fatty acid oxidation might yield valuable therapeutic targets to stabilize the metabolic profile in
Cardiac insulin signaling mediates cellular homeostasis via control of substrate utilization, protein
synthesis, autophagy and cell survival. Suppression of this pathway is associated with increased
7
ACCEPTED MANUSCRIPT
cardiac dysfunction and susceptibility to stress-induced heart failure [56]. Physiologically, binding
of the insulin ligand to the sarcolemmal insulin receptor (IR) activates insulin receptor substrates
pathways. Akt activation stimulates the translocation of GLUT4 to the cell membrane and
subsequent uptake of glucose [32]. The mechanisms mediating impaired insulin signaling in T2D
are not well understood. Recently, an E3 ubiquitin ligase, MG53, has been implicated as an
PT
important regulator of the insulin signaling pathway [57]. Multiple rodent diabetic models (db/db
mice and high fat diet (HFD) mice) exhibit elevated cardiac MG53 protein content, linked with
RI
increased proteosomal degradation of IR and IRS1, and activation of PPARα [57, 58]. Cardiac-
SC
specific overexpression of MG53 induces a phenotype which mimics many of the features of
Some insights into the role of insulin signaling in diabetic cardiac pathology have been gained via
D
genetic manipulation of signaling intermediates. Cardiac insulin receptor knockout (α-myosin heavy
E
PT
chain (αMHC) promotor) decreases cardiomyocyte glucose uptake, increases cardiac oxidative
stress, and reduces mitochondrial function and cardiac efficiency [60-62]. Similarly, cardiac double
CE
knockout of IRS1 and IRS2 (α-MHC promotor) reduces cardiomyocyte ATP content, increases
fibrosis, impairs cardiac metabolism and function, and increases apoptosis leading to eventual
AC
cardiac failure [63]. STZ-induced T1D cardiac pathology is exacerbated in IR-KO mice, with a
greater extent of mitochondrial dysfunction and reduced cardiac efficiency relative to WT mice
[62]. These gene deletion studies suggest that the upstream components of the insulin signaling
pathway (IR, IRS1, IRS2) play an important role in diabetes-associated cardiac pathology, and
8
ACCEPTED MANUSCRIPT
Impaired glucose uptake in the diabetic heart is often linked with reduced expression or activity of
the downstream intermediates in the insulin signaling pathway (Figure 2). Decreased cardiac basal
and insulin-stimulated phosphorylation of Akt is evident in diabetic rodent models [64-66] and
studies using genetic manipulation of the PI3K-Akt nexus in diabetic mice have demonstrated that
these signaling intermediates play a central role in diabetic cardiac pathology. STZ-induced T1D
PT
(dominant-negative PI3K(I) mice, αMHC promotor), and prevented in mice with upregulated
cardiomyocyte PI3K activity (constitutively active PI3K(I) mice, αMHC promotor) [67]. Similarly,
RI
upregulation of PI3K via administration of constitutively active PI3K(I) viral constructs in mice
SC
with established diabetic cardiac pathology (STZ-induced T1D), partially rescued cardiac
dysfunction [68]. Surprisingly, insulin-stimulated glucose uptake has been observed to be decreased
NU
by upregulation of cardiomyocyte PI3K-Akt signaling (via inducible constitutively active PI3K and
MA
myristoylated (active) Akt, αMHC promotor) [69], suggesting that cardiac functional rescue
induced by increased PI3K activity may not be related to restoration of glucose uptake. Given that
D
PI3K is an important signaling focal point for regulation of multiple pathways, it is likely that
E
favorable cardiac outcomes are related to altered metabolism, protein synthesis and/or cell survival.
PT
Interestingly, not all animal studies suggest that diabetes is detrimental in the context of a secondary
CE
cardiac insult. In response to pressure overload surgery, diabetic mice (induced by STZ, db/db, high
fat diet) exhibit less severe (or even abrogated) systolic dysfunction, attributed to the absence of
AC
IR-KO mice and Akt1-deficient mice also exhibit preserved systolic function following pressure
overload, suggesting that the insulin pathway plays an important role in mediating the progression
to heart failure induced by pressure overload [21]. These findings have important implications for
the possible adverse effects of insulin supplementation in settings of high pressure-mediated cardiac
9
ACCEPTED MANUSCRIPT
3.2 AMPK signaling
subunits, and is activated in conditions of stress and starvation via an increase in cellular AMP
concentration [73]. The binding of AMP to AMPK promotes the auto-phosphorylation of threonine
numerous cellular processes including regulation of glycolysis and fatty acid oxidation, autophagy
PT
initiation, and lipid, glycogen and protein synthesis [74] (Figure 2). AMPK mediates tight
RI
regulation of glucose handling via promoting GLUT4 translocation [75], GLUT4-independent
glucose uptake [76], and glycogen synthase phosphorylation [77, 78]. AMPK also binds to
SC
glycogen via its β subunit carbohydrate domain [79, 80], although the role of AMPK in regulating
NU
glycogen content in the heart is not well understood.
MA
Clinically, AMPK activators such as metformin have been used extensively to control
hyperglycemia in T2D patients for over 60 years [81]. Trials are currently underway to evaluate the
D
therapeutic cardiac effects of metformin in T1D patients [82] and numerous studies have
E
demonstrated that metformin treatment improves cardiac outcomes in T1D and T2D rodent models
PT
[83, 84]. Cardiac AMPK downregulation has been reported in animal models of T1D and T2D and
may be an important intervention target [84, 85]. However not all studies have reported decreased
CE
AMPK activity with diabetes. Obese insulin resistant mice (ob/ob) exhibit increased cardiac AMPK
AC
from the renin-angiotensin system [86]. Interestingly, cardiac AMPK modulation in T1D appears
dependent on diabetes duration - AMPK phosphorylation is increased in STZ rats at 4 days post-
injection, yet not different from control at 6 weeks post-STZ injection [87]. Activation of AMPK
via metformin treatment in cultured cardiomyocytes exposed to high glucose improves cell survival
10
ACCEPTED MANUSCRIPT
of Beclin-Bcl2 [88]. Whether cardiac benefit observed with AMPK activation is secondary to
Diabetic patients exhibit impaired exercise capacity, sympathetic activity and blunted inotropic
PT
cardiomyopathy appears to be different in T1D and T2D settings. In STZ-induced T1D rodents,
cardiac β-adrenergic receptors are observed to be desensitized and downregulated [91-95]. In obese
RI
T2D rats, heightened sensitivity to β1- but not β2-adrenergic receptor-mediated chronotropy is
SC
evident [96]. Interestingly, global deletion of the β2 receptor prevented both diastolic and systolic
NU
dysfunction in high fat-fed mice via inhibition of insulin-mediated activation of phosphodiesterase
4D [97]. Given that β2-adrenergic receptors are present in only ~5% of ventricular cardiomyocytes
MA
[98], β2-receptor knockout-induced cardiac outcomes may be related to systemic or atrial changes.
The relationship between β-adrenergic signaling and insulin resistance is emerging as an important
E D
focal point in diabetic cardiac pathology (Figure 2). Short term stimulation of the β-adrenergic
PT
phosphorylation of Akt via protein kinase A [99]. In contrast, long term β-adrenergic stimulation
CE
systemic activation of the β-adrenergic receptor (daily injections of isoproterenol) induces insulin
resistance, and reduces glucose uptake and GLUT4 expression in cardiac tissue; effects which could
be ameliorated with β-blocker treatment [100]. Hyperinsulinemia may play a role in dysregulation
of β-adrenergic signaling in T2D, although the mechanisms are not clear. Insulin-treated neonatal
suggested that hyperinsulinemia promotes β-adrenergic signaling leading to hypertrophy and failure
11
ACCEPTED MANUSCRIPT
[102]. Together, these findings indicate a complex relationship between β-adrenergic and insulin
signaling pathways in the diabetic heart, with each pathway playing an integral role in the
PT
4.1 Glycogen storage
RI
Disruption of metabolic signaling pathways, coupled with altered substrate accessibility and
SC
utilization is associated with irregular fuel storage in the diabetic heart. Glycogen is an important
fuel depot for glucose, well characterized in the liver and skeletal muscle, but its role in the heart is
NU
not well understood. Physiologically, glycogen is regulated via two key enzymes: glycogen
synthase which adds glucose monomers to glycogen chains, and glycogen phosphorylase which
MA
releases glucose-1-phosphate from glycogen [104]. In skeletal muscle, glycogen particles exhibit a
high surface area-to-volume ratio, thus facilitating rapid breakdown in situations where a swift
D
glucose surge is required [105]. Experimentally, in response to fasting, glycogen content is depleted
E
in skeletal muscle [106], but unchanged or even increased [17, 106, 107] in cardiac muscle. It has
PT
been suggested that nutrient deprivation may re-direct glucose to critical tissues such as the heart
CE
In the diabetic context, insulin-sensitive tissues such as cardiac and skeletal muscle are subjected to
a state of glucose deprivation due to impaired glucose uptake induced by insulin deficiency (T1D)
or cellular insulin resistance (T2D). Thus, an expected decrease in skeletal muscle glycogen content
is evident in diabetic subjects [108, 109]. In contrast and paradoxically, increased glycogen in the
human diabetic heart is evident, first documented in early work by Warren (1930), and subsequent
studies in humans and rodents have mostly corroborated this finding [110-136]. However, some
reports of unchanged [129, 137-141] or decreased [140, 142, 143] glycogen are evident (Table 1).
12
ACCEPTED MANUSCRIPT
Interestingly, exercise training has been shown to both elevate [125] and attenuate [132] cardiac
glycogen accumulation in T2D rodents. These inconsistent findings may relate to differences in
diabetes duration, dose, species or age of the animal models. Aged animals appear to be more
susceptible to glycogen accumulation associated with T2D [144], and the dose of streptozotocin
administration is positively correlated with cardiac glycogen content in T1D rats [140]. It could be
PT
degradation. Yet it appears that cardiac glycogen accumulation in diabetes is not explained by
changes in glycogen regulatory enzymes - lower glycogen synthase activity and unchanged or
RI
increased activity of glycogen phosphorylase in various rodent models of T1D and T2D has been
SC
reported [113, 117, 121, 125, 145]. These findings suggest that glycogen accumulation may be
initiated early in disease progression, and snapshot measures at later time points may capture a later
NU
compensatory response, rather than an initial causative enzyme modulatory effect. Alternatively,
MA
glycogen autophagy (‘glycophagy’) has been identified in skeletal muscle, liver and the heart [147-
PT
and recruiting it to the forming autophagosome via binding to γ-aminobutyric acid receptor-
autophagosome fuses with a lysosome where acid α-glucosidase (GAA) degrades glycogen to its
glucose monomers [150]. GAA deficiency in Pompe disease, and inherited lysosome-associated
protein (LAMP2) deficiency, result in severe myocardial glycogen accumulation and cardiac
dysfunction, thus highlighting the importance of lysosomal glycogen breakdown in the heart [151,
insulin, coincident with glycogen accumulation [153]. Disturbances in glycophagy may play a role
13
ACCEPTED MANUSCRIPT
in mediating glycogen accumulation in the diabetic heart in vivo, and further investigation is
warranted.
A shift in reliance on fatty acid oxidation in the diabetic heart is linked with increased fatty acid
PT
upregulation of genes involved in lipid metabolism is evident early in disease progression, detected
RI
lipids, cardiac accumulation of lipid stores has been reported in mouse models of T2D (db/db
SC
mouse) [156] and insulin resistance (high fat-fed mouse) [157], suggesting that upregulation of fatty
NU
acid oxidation is not sufficient to maintain intracellular lipid homeostasis in this setting of increased
fatty acid uptake. Lipid droplets consist of a neutral lipid core containing triacylglycerols and
MA
perilipins [158, 159]. Perilipin 5 is increased in the hearts of T2D (db/db) and T1D (STZ-treated
D
and Akita) mice and cardiac triacylglycerol accumulation and reduced fractional shortening in STZ
E
mice is abrogated by global perilipin5 knockout [160]. Interestingly, evidence of increased lipid
PT
droplets in T2D cardiomyocytes was observed prior to the onset of diastolic dysfunction in 12 week
CE
old male db/db mice [161]. Thus lipid accumulation may be an early, and perhaps primary,
manifestation of diabetic cardiomyopathy and further investigation into the relationship between
AC
Within the cardiomyocyte cytosol, lipid droplets increase in size via fusion, which is mediated by a
multitude of protein complexes, including membrane fusion proteins from the soluble NSF
attachment protein receptor (SNARE) family. In HL-1 cultured cardiomyocytes, oleic acid
incubation increases the lipid droplet-associated pool of the SNARE family protein, soluble NSF
attachment protein 23 (SNAP23), at the expense of the plasma membrane-associated SNAP23 pool
14
ACCEPTED MANUSCRIPT
[162]. Given that SNARE proteins are also involved in GLUT4 translocation, it has been suggested
that increased demand for lipid droplet fusion in diabetes may decrease the availability of SNARE
proteins for GLUT4 vesicle transport thus decreasing insulin sensitivity [162, 163]. Whether this
mechanism plays a role in the development of cardiac insulin resistance in vivo is yet to be
investigated. Fatty acid availability for ATP synthesis is driven by hydrolyzing stored lipids via
adipose triglyceride lipase (Atgl) and hormone sensitive lipase (Hsl) [164]. Cardiac-specific
PT
overexpression of Atgl in T1D (STZ) mice improved the cardiac lipid profile, restored glucose
oxidation and improved functional parameters, whereas Atgl knockdown exacerbated diabetic
RI
cardiac pathology [165]. Similarly, cardiac-specific overexpression of Hsl in T1D (STZ) mice
SC
prevented diabetes-induced lipotoxicity and cardiac fibrosis by facilitating lipid breakdown [166].
Bulk lipid droplet degradation via microtubule-associated protein light chain 3B (LC3B)-mediated
NU
autophagy has been identified in non-cardiac cell types [167], but the role of autophagy in lipid
MA
metabolism in the heart is not yet established. Interestingly, genetic knockout of the autophagy
regulator, forkhead box protein O1 (FoxO1), in T2D mice was associated with reduced lipid
D
accumulation and lipotoxicity, preserved metabolic substrate selectivity and cardiac function, and
E
improved mortality compared to wild-type T2D mice [168]. Although this study did not directly
PT
investigate autophagy-mediated lipid degradation, FoxO1 has been implicated as a key regulator of
transcription of autophagy proteins in the heart [169]. Given that autophagy plays an important role
CE
Extracellular hyperglycemia, impaired glucose uptake, disturbed glycogen handling and metabolic
increased myocardial oxygen consumption and reduced cardiac efficiency [170, 171]. Dysregulated
metabolism may be linked to increased production of reactive oxygen species (ROS) and
development of cardiac oxidative stress in diabetes [172]. A disruption in the homeostatic balance
of ROS management leads to oxidative damage of DNA, proteins and lipids as well as activating
stress-sensitive pathways. Cardiac oxidative stress has been observed in patients with diabetes [173]
PT
and diabetic animals models [68, 174, 175], and urinary levels of oxidation markers have been
RI
[173, 176]. Production of ROS in diabetic hearts and high glucose-incubated cultured
SC
cardiomyocytes has been largely attributed to increased activity of nicotin-amide adenine
dinucleotide phosphate (NADPH) oxidase [177-179] and uncoupling of the mitochondria and
NU
subsequent leakage of the mitochondrial electron transport chain, implicated in declining cardiac
MA
function [180-182]. Other sources of ROS production in the heart include uncoupling of nitric oxide
synthase, activation of protein kinase C, lipoxygenase, and xanthine oxidase [1, 183].
D
Antioxidant treatment strategies have demonstrated some cardiac benefit in experimental animal
E
PT
reduced ROS and oxidation of cardiac myofilament proteins, leading to an improvement in cardiac
CE
diastolic function [182]. Similarly, systemic administration of the antioxidant coenzyme Q10 in
limits diabetes-induced diastolic dysfunction, fibrosis and hypertrophy [175]. ROS production can
diabetic cardiomyopathy. Induction of oxidative stress via hydrogen peroxide treatment in cultured
H9c2 cardiomyoblasts increases autophagy, an effect reversed by treatment with the antioxidant
resveratrol [184]. In the early phase of energy deprivation, cardiomyocyte autophagy induction has
been linked to NADPH oxidase isoform Nox4-derived ROS production in the endoplasmic
reticulum [185, 186]. Evidence suggests that autophagy induction may be a compensatory response
16
ACCEPTED MANUSCRIPT
to oxidative stress with a negative feedback action. Elevated myocardial ROS production and
antioxidant treatment, and conversely, activation of autophagy with rapamycin in this setting
attenuates ROS production [187]. Whether a similar mechanism is evident in diabetic hearts is yet
to be investigated.
PT
Autophagy is a highly conserved and tightly regulated homeostatic process vital for cell growth and
RI
survival. An excess level of autophagic activity has been linked to induction of programmed cell
SC
death [188]. Impaired autophagy is associated with an accumulation of dysfunctional mitochondria
and can trigger stress-response pathways and subsequent cell death via apoptosis [189, 190]. An
NU
understanding of cargo-selective autophagy is emerging - specific degradation processes targeting
MA
and may play an important role in diabetes-induced cardiac pathology [191]. Conflicting literature
D
reports of increased, decreased and unchanged cardiac autophagy in rat and mouse models of
E
diabetic cardiomyopathy have emerged, with no apparent consistency within species, strain,
PT
duration or type of diabetes (previously reviewed in [191]). For example, increased LC3B-positive
myocytes, LC3BII protein expression, phagosome number (from electron micrographs) and
CE
decreased p62 protein expression is evident in atrial biopsies from human T2D patients with
AC
ischemic heart disease [192]. In contrast, decreased Atg5 protein expression and no change in LC3B
is observed in T2D patients with coronary artery disease but without overt signs of cardiomyopathy
autophagy marker LC3BII, T1D rat hearts exhibit increased lysosome number, while T2D mouse
hearts (db/db) exhibit decreased lysosome number [194], suggesting that lysosomal availability
and/or function may play an important role. Inconsistent findings from animal models of diabetes
could be due to differences in severity and type of diabetes, but even highly constrained in vitro
17
ACCEPTED MANUSCRIPT
culture experiments where cardiomyocytes are exposed to high glucose (30mM) yield conflicting
results. Autophagy activation (via rapamycin) exacerbates cell death, and autophagy inhibition (via
3-methyladenine) attenuates cell death in high glucose primary neonatal rat cardiomyocytes [153,
195]. These findings suggest that suppression of autophagy in this context may be a favorable
adaptive response to preserve cell viability. In contrast, activation of autophagy (via metformin-
treatment) decreases high glucose-induced apoptosis in cultured H9c2 cardiomyoblasts [88]. The
PT
differences in these studies could be attributed to the different cell types used. The ‘control’ culture
conditions of ~5mM glucose (for comparison with 30mM glucose) are well-tolerated by primary
RI
neonatal rat ventricular myocytes but may pose a ‘starvation’ challenge to H9c2 cells routinely
SC
maintained in 25mM glucose.
NU
Interventions manipulating cardiac autophagy in experimental diabetic settings have also generated
global genetic knockdown of autophagy initiation proteins (Beclin 1 or Atg16L1 [198]) has also
improved cardiac dysfunction in diabetes. However, the cardiac effects observed in these studies
CE
overexpression in T1D STZ-treated mice (via α-MHC cardiac promotor with tetracycline-controlled
AC
pathology [198]. Given that STZ-induced T1D increases lysosomal content [194], interventions
which upregulate early-autophagy proteins such as Beclin 1 could be detrimental in this disease
setting of heightened lysosomal throughput, but might prove therapeutic in type 2 diabetic db/db
mice where lysosomal availability is more limited. Understanding specific points of disruption in
the autophagic process and how they differ between T1D and T2D is an important priority.
18
ACCEPTED MANUSCRIPT
6. Conclusions
provided considerable mechanistic and molecular insight into disease characteristics. Diabetes-
related systemic disturbances in glucose, insulin and fatty acids, facilitate shifts in the cardiac
PT
metabolic profile and alterations in key cardiac signaling pathways. Decreased insulin signaling,
RI
and an aberrant response to β-adrenergic stimulation, impact on cardiomyocyte substrate utilization,
storage of glucose and lipids, and cell death via apoptosis and autophagy. AMPK signaling
SC
disturbance is evident but not well characterized in the diabetic heart. Disruptions in these signaling
NU
pathways, and energy stress responses such as oxidative stress and autophagy dysregulation, are
likely contributors to cardiomyocyte death and to impaired functional performance in the diabetic
MA
heart (Figure 1). Genetic manipulation of cardiac metabolic pathways, signaling intermediates, and
autophagy proteins have provided important insights into the molecular mechanisms of diabetic
D
cardiomyopathy has not yet been achieved. In some cases, pre-clinical findings have not translated
PT
to the human patient setting. Relative ischemic cardioprotection observed in some diabetic rodent
CE
models is not evident in diabetic patients where worse outcomes post-ischemia are evident [17].
Impaired cardiac glucose uptake and utilization, well-described in obese and lean diabetic rodents,
AC
are evident in T2D male but not female patients [199]. Interestingly, metformin treatment
exacerbated glucose handling abnormalities in male T2D patients, despite evidence of some
characterizing sex differences and interrogation of the translational value of rodent models of
19
ACCEPTED MANUSCRIPT
References
1. K. Huynh, B.C. Bernardo, J.R. McMullen, R.H. Ritchie, Diabetic cardiomyopathy:
mechanisms and new treatment strategies targeting antioxidant signaling pathways,
Pharmacol Ther 142 (2014) 375-415.
2. C.S. Lam, Diabetic cardiomyopathy: An expression of stage B heart failure with preserved
ejection fraction, Diab Vasc Dis Res 12 (2015) 234-238.
3. H. Bugger, E.D. Abel, Molecular mechanisms of diabetic cardiomyopathy, Diabetologia 57
(2014) 660-671.
4. B.M. Fisher, G. Gillen, G.B. Lindop, H.J. Dargie, B.M. Frier, Cardiac function and coronary
arteriography in asymptomatic type 1 (insulin-dependent) diabetic patients: evidence for a
specific diabetic heart disease, Diabetologia 29 (1986) 706-712.
5. G. Jia, A. Whaley-Connell, J.R. Sowers, Diabetic cardiomyopathy: a hyperglycaemia- and
PT
insulin-resistance-induced heart disease, Diabetologia (2017)
6. S. Dandamudi, J. Slusser, D.W. Mahoney, M.M. Redfield, R.J. Rodeheffer, H.H. Chen, The
prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County,
RI
Minnesota, J Card Fail 20 (2014) 304-309.
7. V.C. Patil, H.V. Patil, K.B. Shah, J.D. Vasani, P. Shetty, Diastolic dysfunction in
SC
asymptomatic type 2 diabetes mellitus with normal systolic function, Journal of
cardiovascular disease research 2 (2011) 213-222.
8. M. Shimabukuro, N. Higa, T. Asahi, K. Yamakawa, Y. Oshiro, M. Higa, H. Masuzaki,
NU
Impaired glucose tolerance, but not impaired fasting glucose, underlies left ventricular
diastolic dysfunction, Diabetes Care 34 (2011) 686-690.
9. A.M. From, C.G. Scott, H.H. Chen, The development of heart failure in patients with
diabetes mellitus and pre-clinical diastolic dysfunction a population-based study, J Am Coll
MA
1943-1949.
11. L. van Heerebeek, N. Hamdani, M.L. Handoko, I. Falcao-Pires, R.J. Musters, K.
E
J. van der Velden, G.J. Stienen, G.J. Laarman, H.W. Niessen, W.J. Paulus, Diastolic
stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end
products, and myocyte resting tension, Circulation 117 (2008) 43-51.
CE
12. K.J. Nadeau, J.G. Regensteiner, T.A. Bauer, M.S. Brown, J.L. Dorosz, A. Hull, P. Zeitler,
B. Draznin, J.E. Reusch, Insulin resistance in adolescents with type 1 diabetes and its
relationship to cardiovascular function, J Clin Endocrinol Metab 95 (2010) 513-521.
AC
13. T.J. Bradley, C. Slorach, F.H. Mahmud, D.B. Dunger, J. Deanfield, L. Deda, Y. Elia, R.L.
Har, W. Hui, R. Moineddin, H.N. Reich, J.W. Scholey, L. Mertens, E. Sochett, D.Z.
Cherney, Early changes in cardiovascular structure and function in adolescents with type 1
diabetes, Cardiovasc Diabetol 15 (2016) 31.
14. M. Diamant, H.J. Lamb, Y. Groeneveld, E.L. Endert, J.W. Smit, J.J. Bax, J.A. Romijn, A.
de Roos, J.K. Radder, Diastolic dysfunction is associated with altered myocardial
metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes
mellitus, J Am Coll Cardiol 42 (2003) 328-335.
15. A.S. Jaffe, J.J. Spadaro, K. Schechtman, R. Roberts, E.M. Geltman, B.E. Sobel, Increased
congestive heart failure after myocardial infarction of modest extent in patients with
diabetes mellitus, American heart journal 108 (1984) 31-37.
16. A. Goyal, N. Agrawal, Ischemic preconditioning: Interruption of various disorders, J Saudi
Heart Assoc 29 (2017) 116-127.
20
ACCEPTED MANUSCRIPT
17. M.E. Reichelt, K.M. Mellor, J.R. Bell, C. Chandramouli, J.P. Headrick, L.M. Delbridge,
Sex, sex steroids, and diabetic cardiomyopathy: making the case for experimental focus, Am
J Physiol Heart Circ Physiol 305 (2013) H779-792.
18. B.A. Christopher, H.M. Huang, J.M. Berthiaume, T.A. McElfresh, X. Chen, C.M. Croniger,
R.F. Muzic, Jr., M.P. Chandler, Myocardial insulin resistance induced by high fat feeding in
heart failure is associated with preserved contractile function, American journal of
physiology Heart and circulatory physiology 299 (2010) H1917-1927.
19. J.H. Rennison, T.A. McElfresh, X. Chen, V.R. Anand, B.D. Hoit, C.L. Hoppel, M.P.
Chandler, Prolonged exposure to high dietary lipids is not associated with lipotoxicity in
heart failure, Journal of molecular and cellular cardiology 46 (2009) 883-890.
20. J.H. Rennison, T.A. McElfresh, I.C. Okere, E.J. Vazquez, H.V. Patel, A.B. Foster, K.K.
Patel, Q. Chen, B.D. Hoit, K.Y. Tserng, M.O. Hassan, C.L. Hoppel, M.P. Chandler, High-
PT
fat diet postinfarction enhances mitochondrial function and does not exacerbate left
ventricular dysfunction, American journal of physiology Heart and circulatory physiology
292 (2007) H1498-1506.
RI
21. I. Shimizu, T. Minamino, H. Toko, S. Okada, H. Ikeda, N. Yasuda, K. Tateno, J. Moriya, M.
Yokoyama, A. Nojima, G.Y. Koh, H. Akazawa, I. Shiojima, C.R. Kahn, E.D. Abel, I.
Komuro, Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by
SC
pressure overload in rodents, The Journal of clinical investigation 120 (2010) 1506-1514.
22. W.C. Stanley, G.D. Lopaschuk, J.G. McCormack, Regulation of energy substrate
metabolism in the diabetic heart, Cardiovasc Res 34 (1997) 25-33.
NU
23. L. Yang, D. Zhao, J. Ren, J. Yang, Endoplasmic reticulum stress and protein quality control
in diabetic cardiomyopathy, Biochim Biophys Acta 1852 (2015) 209-218.
24. K.M. Mellor, M.A. Brimble, L.M. Delbridge, Glucose as an agent of post-translational
MA
modification in diabetes--New cardiac epigenetic insights, Life Sci 129 (2015) 48-53.
25. K.R. Bidasee, K. Nallani, Y. Yu, R.R. Cocklin, Y. Zhang, M. Wang, U.D. Dincer, H.R.
Besch, Jr., Chronic diabetes increases advanced glycation end products on cardiac ryanodine
receptors/calcium-release channels, Diabetes 52 (2003) 1825-1836.
D
26. K.R. Bidasee, Y. Zhang, C.H. Shao, M. Wang, K.P. Patel, U.D. Dincer, H.R. Besch, Jr.,
Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic
E
linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the
heart, Life Sci 92 (2013) 621-627.
28. K.M. Mellor, I.R. Wendt, R.H. Ritchie, L.M. Delbridge, Fructose diet treatment in mice
CE
PT
Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts,
Metabolism 46 (1997) 1333-1338.
41. A. Kashiwagi, T. Obata, M. Suzaki, Y. Takagi, Y. Kida, T. Ogawa, Y. Tanaka, T. Asahina,
RI
M. Ikebuchi, Y. Saeki, et al., Increase in cardiac muscle fructose content in streptozotocin-
induced diabetic rats, Metabolism 41 (1992) 1041-1046.
42. L.M. Delbridge, V.L. Benson, R.H. Ritchie, K.M. Mellor, Diabetic Cardiomyopathy: The
SC
Case for a Role of Fructose in Disease Etiology, Diabetes 65 (2016) 3521-3528.
43. J. Buchanan, P.K. Mazumder, P. Hu, G. Chakrabarti, M.W. Roberts, U.J. Yun, R.C.
Cooksey, S.E. Litwin, E.D. Abel, Reduced cardiac efficiency and altered substrate
NU
metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse
models of insulin resistance and obesity, Endocrinology 146 (2005) 5341-5349.
44. L. Hue, H. Taegtmeyer, The Randle cycle revisited: a new head for an old hat, American
MA
on isolated working diabetic rat heart, The American journal of physiology 261 (1991)
H1053-1059.
PT
47. O.J. How, T.S. Larsen, A.D. Hafstad, A. Khalid, E.S. Myhre, A.J. Murray, N.T. Boardman,
M. Cole, K. Clarke, D.L. Severson, E. Aasum, Rosiglitazone treatment improves cardiac
efficiency in hearts from diabetic mice, Arch Physiol Biochem 113 (2007) 211-220.
CE
49. H. Taegtmeyer, P. McNulty, M.E. Young, Adaptation and maladaptation of the heart in
diabetes: Part I: general concepts, Circulation 105 (2002) 1727-1733.
50. B.N. Finck, J.J. Lehman, T.C. Leone, M.J. Welch, M.J. Bennett, A. Kovacs, X. Han, R.W.
Gross, R. Kozak, G.D. Lopaschuk, D.P. Kelly, The cardiac phenotype induced by
PPARalpha overexpression mimics that caused by diabetes mellitus, J Clin Invest 109
(2002) 121-130.
51. D.R. Cha, J.Y. Han, D.M. Su, Y. Zhang, X. Fan, M.D. Breyer, Y. Guan, Peroxisome
proliferator-activated receptor-alpha deficiency protects aged mice from insulin resistance
induced by high-fat diet, American journal of nephrology 27 (2007) 479-482.
52. E. Aasum, D.D. Belke, D.L. Severson, R.A. Riemersma, M. Cooper, M. Andreassen, T.S.
Larsen, Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM
17.0744, a novel PPAR-alpha activator, Am J Physiol Heart Circ Physiol 283 (2002) H949-
957.
22
ACCEPTED MANUSCRIPT
53. A.N. Carley, L.M. Semeniuk, Y. Shimoni, E. Aasum, T.S. Larsen, J.P. Berger, D.L.
Severson, Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist
improves cardiac metabolism but not contractile function, American journal of physiology
Endocrinology and metabolism 286 (2004) E449-455.
54. S. Sharma, R. Taliyan, Histone deacetylase inhibitors: Future therapeutics for insulin
resistance and type 2 diabetes, Pharmacological research : the official journal of the Italian
Pharmacological Society 113 (2016) 320-326.
55. T.I. Lee, Y.H. Kao, W.C. Tsai, C.C. Chung, Y.C. Chen, Y.J. Chen, HDAC Inhibition
Modulates Cardiac PPARs and Fatty Acid Metabolism in Diabetic Cardiomyopathy, PPAR
Res 2016 (2016) 5938740.
56. C. Riehle, E.D. Abel, Insulin Signaling and Heart Failure, Circulation research 118 (2016)
1151-1169.
PT
57. R. Song, W. Peng, Y. Zhang, F. Lv, H.K. Wu, J. Guo, Y. Cao, Y. Pi, X. Zhang, L. Jin, M.
Zhang, P. Jiang, F. Liu, S. Meng, C.M. Cao, R.P. Xiao, Central role of E3 ubiquitin ligase
MG53 in insulin resistance and metabolic disorders, Nature 494 (2013) 375-379.
RI
58. F. Liu, R. Song, Y. Feng, J. Guo, Y. Chen, Y. Zhang, T. Chen, Y. Wang, Y. Huang, C.Y. Li,
C. Cao, Y. Zhang, X. Hu, R.P. Xiao, Upregulation of MG53 Induces Diabetic
Cardiomyopathy Through Transcriptional Activation of Peroxisome Proliferation-Activated
SC
Receptor alpha, Circulation 131 (2015) 795-804.
59. Y. Zhang, H.K. Wu, F. Lv, R.P. Xiao, MG53, biological function and potential as a
therapeutic target, Molecular pharmacology (2017)
NU
60. D.D. Belke, S. Betuing, M.J. Tuttle, C. Graveleau, M.E. Young, M. Pham, D. Zhang, R.C.
Cooksey, D.A. McClain, S.E. Litwin, H. Taegtmeyer, D. Severson, C.R. Kahn, E.D. Abel,
Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein
MA
62. H. Bugger, C. Riehle, B. Jaishy, A.R. Wende, J. Tuinei, D. Chen, J. Soto, K.M. Pires, S.
Boudina, H.A. Theobald, I. Luptak, B. Wayment, X. Wang, S.E. Litwin, B.C. Weimer, E.D.
PT
Abel, Genetic loss of insulin receptors worsens cardiac efficiency in diabetes, J Mol Cell
Cardiol 52 (2012) 1019-1026.
63. Y. Qi, Z. Xu, Q. Zhu, C. Thomas, R. Kumar, H. Feng, D.E. Dostal, M.F. White, K.M.
CE
Baker, S. Guo, Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by
p38alpha MAPK during insulin resistance, Diabetes 62 (2013) 3887-3900.
64. M. Shum, K. Bellmann, P. St-Pierre, A. Marette, Pharmacological inhibition of S6K1
AC
increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice,
Diabetologia 59 (2016) 592-603.
65. H. Liu, H.Y. Liu, Y.N. Jiang, N. Li, Protective effect of thymoquinone improves
cardiovascular function, and attenuates oxidative stress, inflammation and apoptosis by
mediating the PI3K/Akt pathway in diabetic rats, Molecular medicine reports 13 (2016)
2836-2842.
66. Q. Chen, T. Xu, D. Li, D. Pan, P. Wu, Y. Luo, Y. Ma, Y. Liu, JNK/PI3K/Akt signaling
pathway is involved in myocardial ischemia/reperfusion injury in diabetic rats: effects of
salvianolic acid A intervention, American journal of translational research 8 (2016) 2534-
2548.
67. R.H. Ritchie, J.E. Love, K. Huynh, B.C. Bernardo, D.C. Henstridge, H. Kiriazis, Y.K.
Tham, G. Sapra, C. Qin, N. Cemerlang, E.J. Boey, K. Jandeleit-Dahm, X.J. Du, J.R.
McMullen, Enhanced phosphoinositide 3-kinase(p110alpha) activity prevents diabetes-
23
ACCEPTED MANUSCRIPT
induced cardiomyopathy and superoxide generation in a mouse model of diabetes,
Diabetologia 55 (2012) 3369-3381.
68. D. Prakoso, M.J. DeBlasio, C. Qin, S. Rosli, H. Kiriazis, H. Qian, X.J. Du, K.L. Weeks, P.
Gregorevic, J.R. McMullen, R.H. Ritchie, Phosphoinositide 3-Kinase (p110alpha) Gene
Delivery Limits Diabetes-induced Cardiac NADPH Oxidase and Cardiomyopathy in a
Mouse Model with Established Diastolic Dysfunction, Clin Sci (Lond) 131 (2017) 1345-
1360.
69. Y. Zhu, R.O. Pereira, B.T. O'Neill, C. Riehle, O. Ilkun, A.R. Wende, T.A. Rawlings, Y.C.
Zhang, Q. Zhang, A. Klip, I. Shiojima, K. Walsh, E.D. Abel, Cardiac PI3K-Akt impairs
insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation, Mol
Endocrinol 27 (2013) 172-184.
70. D. Abdurrachim, M. Nabben, V. Hoerr, M.T. Kuhlmann, P. Bovenkamp, J. Ciapaite, I.M.E.
PT
Geraets, W. Coumans, J. Luiken, J.F.C. Glatz, M. Schafers, K. Nicolay, C. Faber, S.
Hermann, J.J. Prompers, Diabetic db/db mice do not develop heart failure upon pressure
overload: a longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural,
RI
and functional adaptations, Cardiovascular research 113 (2017) 1148-1160.
71. R.E. Brainard, L.J. Watson, A.M. Demartino, K.R. Brittian, R.D. Readnower, A.A. Boakye,
D. Zhang, J.D. Hoetker, A. Bhatnagar, S.P. Baba, S.P. Jones, High fat feeding in mice is
SC
insufficient to induce cardiac dysfunction and does not exacerbate heart failure, PloS one 8
(2013) e83174.
72. D.J. Chess, R.J. Khairallah, K.M. O'Shea, W. Xu, W.C. Stanley, A high-fat diet increases
NU
adiposity but maintains mitochondrial oxidative enzymes without affecting development of
heart failure with pressure overload, American journal of physiology Heart and circulatory
physiology 297 (2009) H1585-1593.
MA
73. D. Grahame Hardie, AMP-activated protein kinase: a key regulator of energy balance with
many roles in human disease, Journal of internal medicine 276 (2014) 543-559.
74. S.C. Bairwa, N. Parajuli, J.R. Dyck, The role of AMPK in cardiomyocyte health and
survival, Biochimica et biophysica acta 1862 (2016) 2199-2210.
D
75. R.R. Russell, 3rd, R. Bergeron, G.I. Shulman, L.H. Young, Translocation of myocardial
GLUT-4 and increased glucose uptake through activation of AMPK by AICAR, Am J
E
Vaulont, D.G. Hardie, B.F. Hansen, E.A. Richter, J.F. Wojtaszewski, The alpha2-5'AMP-
activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is
responsive to glucose loading, Diabetes 53 (2004) 3074-3081.
AC
78. R. Halse, L.G. Fryer, J.G. McCormack, D. Carling, S.J. Yeaman, Regulation of glycogen
synthase by glucose and glycogen: a possible role for AMP-activated protein kinase,
Diabetes 52 (2003) 9-15.
79. A. McBride, S. Ghilagaber, A. Nikolaev, D.G. Hardie, The glycogen-binding domain on the
AMPK beta subunit allows the kinase to act as a glycogen sensor, Cell metabolism 9 (2009)
23-34.
80. G. Polekhina, A. Gupta, B.J. Michell, B. van Denderen, S. Murthy, S.C. Feil, I.G. Jennings,
D.J. Campbell, L.A. Witters, M.W. Parker, B.E. Kemp, D. Stapleton, AMPK beta subunit
targets metabolic stress sensing to glycogen, Current biology : CB 13 (2003) 867-871.
81. H. An, L. He, Current understanding of metformin effect on the control of hyperglycemia in
diabetes, The Journal of endocrinology 228 (2016) R97-106.
82. J.R. Petrie, N. Chaturvedi, I. Ford, M. Brouwers, N. Greenlaw, T. Tillin, I. Hramiak, A.D.
Hughes, A.J. Jenkins, B.E.K. Klein, R. Klein, T.C. Ooi, P. Rossing, C.D.A. Stehouwer, N.
Sattar, H.M. Colhoun, R.S. Group, Cardiovascular and metabolic effects of metformin in
24
ACCEPTED MANUSCRIPT
patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled
trial, Lancet Diabetes Endocrinol 5 (2017) 597-609.
83. S. Verma, J.H. McNeill, Metformin improves cardiac function in isolated streptozotocin-
diabetic rat hearts, Am J Physiol 266 (1994) H714-719.
84. Z. Xie, K. Lau, B. Eby, P. Lozano, C. He, B. Pennington, H. Li, S. Rathi, Y. Dong, R. Tian,
D. Kem, M.H. Zou, Improvement of cardiac functions by chronic metformin treatment is
associated with enhanced cardiac autophagy in diabetic OVE26 mice, Diabetes 60 (2011)
1770-1778.
85. A. Daniels, M. van Bilsen, B.J. Janssen, A.E. Brouns, J.P. Cleutjens, T.H. Roemen, G.
Schaart, J. van der Velden, G.J. van der Vusse, F.A. van Nieuwenhoven, Impaired cardiac
functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not
structural, remodelling, Acta Physiol (Oxf) 200 (2010) 11-22.
PT
86. I. Tabbi-Anneni, J. Buchanan, R.C. Cooksey, E.D. Abel, Captopril normalizes insulin
signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts,
Endocrinology 149 (2008) 4043-4050.
RI
87. G. Kewalramani, D. An, M.S. Kim, S. Ghosh, D. Qi, A. Abrahani, T. Pulinilkunnil, V.
Sharma, R.B. Wambolt, M.F. Allard, S.M. Innis, B. Rodrigues, AMPK control of
myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes, J
SC
Mol Cell Cardiol 42 (2007) 333-342.
88. C. He, H. Zhu, H. Li, M.H. Zou, Z. Xie, Dissociation of Bcl-2-Beclin1 complex by activated
AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in
NU
diabetes, Diabetes 62 (2013) 1270-1281.
89. R. Scognamiglio, A. Avogaro, D. Casara, C. Crepaldi, M. Marin, M. Palisi, R. Mingardi, G.
Erle, G. Fasoli, S. Dalla Volta, Myocardial dysfunction and adrenergic cardiac innervation
MA
PT
GRK2-mediated beta2AR internalization to attenuate betaAR signaling in cardiomyocytes,
Cellular signalling 27 (2015) 707-715.
102. Q. Fu, Q. Wang, Y.K. Xiang, Insulin and beta Adrenergic Receptor Signaling: Crosstalk in
RI
Heart, Trends in endocrinology and metabolism: TEM 28 (2017) 416-427.
103. S. Mangmool, T. Denkaew, W. Parichatikanond, H. Kurose, beta-Adrenergic Receptor and
Insulin Resistance in the Heart, Biomolecules & therapeutics 25 (2017) 44-56.
SC
104. C. Chandramouli, U. Varma, E.M. Stevens, R.P. Xiao, D.I. Stapleton, K.M. Mellor, L.M.
Delbridge, Myocardial glycogen dynamics: new perspectives on disease mechanisms,
Clinical and experimental pharmacology & physiology 42 (2015) 415-425.
NU
105. J.H. Ryu, J. Drain, J.H. Kim, S. McGee, A. Gray-Weale, L. Waddington, G.J. Parker, M.
Hargreaves, S.H. Yoo, D. Stapleton, Comparative structural analyses of purified glycogen
particles from rat liver, human skeletal muscle and commercial preparations, Int J Biol
MA
107. M.C. Gannon, F.Q. Nuttall, Effect of prolonged starvation on glycogen synthase and
glycogen synthase phosphatase activity in rat heart, J Nutr 114 (1984) 2147-2154.
E
108. J. He, D.E. Kelley, Muscle glycogen content in type 2 diabetes mellitus, Am J Physiol
Endocrinol Metab 287 (2004) E1002-1007.
PT
109. A.W. Thorburn, B. Gumbiner, F. Bulacan, G. Brechtel, R.R. Henry, Multiple defects in
muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin
dependent diabetes mellitus, J Clin Invest 87 (1991) 489-495.
CE
110. R.A. Rizza, M.F. Crass, 3rd, J.C. Shipp, Effect of insulin treatment in vivo on heart
glycerides and glycogen of alloxan-diabetic rats, Metabolism: clinical and experimental 20
(1971) 539-543.
AC
26
ACCEPTED MANUSCRIPT
116. N.P. Lebkova, M.F. Bondarenko, O.E. Kolesova, G.P. Azarian, [Ultrastructural
manifestations of early metabolic disorders in the myocardium of dogs with alloxan
diabetes], Biulleten' eksperimental'noi biologii i meditsiny 89 (1980) 614-617.
117. M.R. Laughlin, W.A. Petit, Jr., R.G. Shulman, E.J. Barrett, Measurement of myocardial
glycogen synthesis in diabetic and fasted rats, Am J Physiol 258 (1990) E184-190.
118. O. Kraupp, L. Adler-Kastner, H. Niessner, B. Plank, The effects of starvation and of acute
and chronic alloxan diabetes on myocardial substrate levels and on liver glycogen in the rat
in vivo, Eur J Biochem 2 (1967) 197-214.
119. Y.C. Hsiao, K. Suzuki, H. Abe, T. Toyota, Ultrastructural alterations in cardiac muscle of
diabetic BB Wistar rats, Virchows Archiv A, Pathological anatomy and histopathology 411
(1987) 45-52.
120. M. Higuchi, K. Miyagi, J. Nakasone, M. Sakanashi, Role of high glycogen in underperfused
PT
diabetic rat hearts with added norepinephrine, J Cardiovasc Pharmacol 26 (1995) 899-907.
121. M. Dervisevik, S. Dinevska-Kovkarovska, M. Dimitrovska, N. Cipanovska, B. Miova, High
dose of aspirin moderates diabetes-induced changes of heart glycogen/glucose metabolism
RI
in rats, The journal of physiological sciences : JPS 64 (2014) 411-420.
122. V. Chen, C.D. Ianuzzo, B.C. Fong, J.J. Spitzer, The effects of acute and chronic diabetes on
myocardial metabolism in rats, Diabetes 33 (1984) 1078-1084.
SC
123. S. Bhimji, D.V. Godin, J.H. McNeill, Myocardial ultrastructural changes in alloxan-induced
diabetes in rabbits, Acta anatomica 125 (1986) 195-200.
124. C. Alfarano, S. Suffredini, O. Fantappie, A. Mugelli, E. Cerbai, M.E. Manni, L. Raimondi,
NU
The effect of losartan treatment on the response of diabetic cardiomyocytes to ATP
depletion, Pharmacol Res 63 (2011) 225-232.
125. J. Shearer, K.D. Ross, C.C. Hughey, V.L. Johnsen, D.S. Hittel, D.L. Severson, Exercise
MA
training does not correct abnormal cardiac glycogen accumulation in the db/db mouse model
of type 2 diabetes, Am J Physiol Endocrinol Metab 301 (2011) E31-39.
126. M. Sakakibara, A. Hirashiki, X.W. Cheng, Y. Bando, K. Ohshima, T. Okumura, H.
Funahashi, S. Ohshima, T. Murohara, Association of diabetes mellitus with myocardial
D
127. P. Rosen, L. Herberg, H. Reinauer, Different types of postinsulin receptor defects contribute
to insulin resistance in hearts of obese Zucker rats, Endocrinology 119 (1986) 1285-1291.
PT
128. M. Reyes, M.E. Steinhelper, J.A. Alvarez, D. Escobedo, J. Pearce, J.W. Valvano, B.H.
Pollock, C.L. Wei, A. Kottam, D. Altman, S. Bailey, S. Thomsen, S. Lee, J.T. Colston, J.H.
Oh, G.L. Freeman, M.D. Feldman, Impact of physiological variables and genetic
CE
PT
diabetology 14 (2015) 97.
137. Z.J. Wang, Q. Liu, P.P. Li, C.H. Zou, Z.F. Shen, Effect of GCP-02, a PPARalpha/gamma
dual activator, on glucose and lipid metabolism in insulin-resistant mice, European journal
RI
of pharmacology 580 (2008) 277-283.
138. W.C. Stanley, J.L. Hall, K.R. Smith, G.D. Cartee, T.A. Hacker, J.A. Wisneski, Myocardial
glucose transporters and glycolytic metabolism during ischemia in hyperglycemic diabetic
SC
swine, Metabolism 43 (1994) 61-69.
139. L.S. Mansor, K. Mehta, D. Aksentijevic, C.A. Carr, T. Lund, M.A. Cole, L. Le Page, L.
Sousa Fialho Mda, M.J. Shattock, E. Aasum, K. Clarke, D.J. Tyler, L.C. Heather, Increased
NU
oxidative metabolism following hypoxia in the type 2 diabetic heart, despite normal hypoxia
signalling and metabolic adaptation, The Journal of physiology 594 (2016) 307-320.
140. L.S. Mansor, E.R. Gonzalez, M.A. Cole, D.J. Tyler, J.H. Beeson, K. Clarke, C.A. Carr, L.C.
MA
Heather, Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with
low dose streptozotocin, Cardiovascular diabetology 12 (2013) 136.
141. I. Das, Studies on glycogen metabolism in normal and diabetic rat heart in vivo, Can J
Biochem 51 (1973) 637-641.
D
142. B.L. Leonard, R.N. Watson, K.M. Loomes, A.R. Phillips, G.J. Cooper, Insulin resistance in
the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes,
E
glycogen synthase and synthase phosphatase activity in rats fed diets high in protein, fat or
carbohydrate, J Nutr 115 (1985) 243-251.
144. L.G. Chuffa, F.R. Seiva, Combined effects of age and diet-induced obesity on biochemical
CE
parameters and cardiac energy metabolism in rats, Indian J Biochem Biophys 50 (2013) 40-
47.
145. T.B. Miller, Jr., A dual role for insulin in the regulation of cardiac glycogen synthase, J Biol
AC
28
ACCEPTED MANUSCRIPT
150. L.M. Delbridge, K.M. Mellor, D.J. Taylor, R.A. Gottlieb, Myocardial autophagic energy
stress responses--macroautophagy, mitophagy, and glycophagy, American journal of
physiology Heart and circulatory physiology 308 (2015) H1194-1204.
151. A. Fayssoil, Cardiomyopathy in Pompe's disease, European journal of internal medicine 19
(2008) 57-59.
152. Z. Cheng, Q. Fang, Danon disease: focusing on heart, Journal of human genetics 57 (2012)
407-410.
153. K.M. Mellor, U. Varma, D.I. Stapleton, L.M. Delbridge, Cardiomyocyte glycophagy is
regulated by insulin and exposure to high extracellular glucose, American journal of
physiology Heart and circulatory physiology 306 (2014) H1240-1245.
154. J.J. Luiken, Y. Arumugam, D.J. Dyck, R.C. Bell, M.M. Pelsers, L.P. Turcotte, N.N. Tandon,
J.F. Glatz, A. Bonen, Increased rates of fatty acid uptake and plasmalemmal fatty acid
PT
transporters in obese Zucker rats, J Biol Chem 276 (2001) 40567-40573.
155. G.A. Cook, E.N. Lavrentyev, K. Pham, E.A. Park, Streptozotocin diabetes increases mRNA
expression of ketogenic enzymes in the rat heart, Biochim Biophys Acta 1861 (2017) 307-
RI
312.
156. D. Abdurrachim, M. Nabben, V. Hoerr, M.T. Kuhlmann, P. Bovenkamp, J. Ciapaite, I.M.E.
Geraets, W. Coumans, J. Luiken, J.F.C. Glatz, M. Schafers, K. Nicolay, C. Faber, S.
SC
Hermann, J.J. Prompers, Diabetic db/db mice do not develop heart failure upon pressure
overload: A longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural,
and functional adaptations, Cardiovasc Res (2017)
NU
157. D. de Gonzalo-Calvo, R.W. van der Meer, L.J. Rijzewijk, J.W. Smit, E. Revuelta-Lopez, L.
Nasarre, J.C. Escola-Gil, H.J. Lamb, V. Llorente-Cortes, Serum microRNA-1 and
microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes, Sci
MA
159. H. Wang, U. Sreenivasan, D.W. Gong, K.A. O'Connell, E.R. Dabkowski, P.A. Hecker, N.
Ionica, M. Konig, A. Mahurkar, Y. Sun, W.C. Stanley, C. Sztalryd, Cardiomyocyte-specific
E
Connell, J.R. Sowers, Obesity-related alterations in cardiac lipid profile and nondipping
blood pressure pattern during transition to diastolic dysfunction in male db/db mice,
Endocrinology 154 (2013) 159-171.
162. P. Bostrom, L. Andersson, M. Rutberg, J. Perman, U. Lidberg, B.R. Johansson, J.
Fernandez-Rodriguez, J. Ericson, T. Nilsson, J. Boren, S.O. Olofsson, SNARE proteins
mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity, Nat
Cell Biol 9 (2007) 1286-1293.
163. T.H. Sollner, Lipid droplets highjack SNAREs, Nat Cell Biol 9 (2007) 1219-1220.
164. I.J. Goldberg, C.M. Trent, P.C. Schulze, Lipid metabolism and toxicity in the heart, Cell
Metab 15 (2012) 805-812.
165. T. Pulinilkunnil, P.C. Kienesberger, J. Nagendran, T.J. Waller, M.E. Young, E.E. Kershaw,
G. Korbutt, G. Haemmerle, R. Zechner, J.R. Dyck, Myocardial adipose triglyceride lipase
overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy,
Diabetes 62 (2013) 1464-1477.
29
ACCEPTED MANUSCRIPT
166. M. Ueno, J. Suzuki, Y. Zenimaru, S. Takahashi, T. Koizumi, S. Noriki, O. Yamaguchi, K.
Otsu, W.J. Shen, F.B. Kraemer, I. Miyamori, Cardiac overexpression of hormone-sensitive
lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice, Am J
Physiol Endocrinol Metab 294 (2008) E1109-1118.
167. R. Singh, S. Kaushik, Y. Wang, Y. Xiang, I. Novak, M. Komatsu, K. Tanaka, A.M. Cuervo,
M.J. Czaja, Autophagy regulates lipid metabolism, Nature 458 (2009) 1131-1135.
168. P.K. Battiprolu, B. Hojayev, N. Jiang, Z.V. Wang, X. Luo, M. Iglewski, J.M. Shelton, R.D.
Gerard, B.A. Rothermel, T.G. Gillette, S. Lavandero, J.A. Hill, Metabolic stress-induced
activation of FoxO1 triggers diabetic cardiomyopathy in mice, The Journal of clinical
investigation 122 (2012) 1109-1118.
169. S. Paula-Gomes, D.A. Goncalves, A.M. Baviera, N.M. Zanon, L.C. Navegantes, I.C.
Kettelhut, Insulin suppresses atrophy- and autophagy-related genes in heart tissue and
PT
cardiomyocytes through AKT/FOXO signaling, Hormone and metabolic research =
Hormon- und Stoffwechselforschung = Hormones et metabolisme 45 (2013) 849-855.
170. O.J. How, E. Aasum, D.L. Severson, W.Y. Chan, M.F. Essop, T.S. Larsen, Increased
RI
myocardial oxygen consumption reduces cardiac efficiency in diabetic mice, Diabetes 55
(2006) 466-473.
171. P.K. Mazumder, B.T. O'Neill, M.W. Roberts, J. Buchanan, U.J. Yun, R.C. Cooksey, S.
SC
Boudina, E.D. Abel, Impaired cardiac efficiency and increased fatty acid oxidation in
insulin-resistant ob/ob mouse hearts, Diabetes 53 (2004) 2366-2374.
172. A. Faria, S.J. Persaud, Cardiac oxidative stress in diabetes: Mechanisms and therapeutic
NU
potential, Pharmacology & therapeutics 172 (2017) 50-62.
173. X. Liu, W. Gan, Y. Zou, B. Yang, Z. Su, J. Deng, L. Wang, J. Cai, Elevated Levels of
Urinary Markers of Oxidative DNA and RNA Damage in Type 2 Diabetes with
MA
175. M.J. De Blasio, K. Huynh, C. Qin, S. Rosli, H. Kiriazis, A. Ayer, N. Cemerlang, R. Stocker,
X.J. Du, J.R. McMullen, R.H. Ritchie, Therapeutic targeting of oxidative stress with
E
147.
176. T. Nishikawa, T. Sasahara, S. Kiritoshi, K. Sonoda, T. Senokuchi, T. Matsuo, D. Kukidome,
N. Wake, T. Matsumura, N. Miyamura, M. Sakakida, H. Kishikawa, E. Araki, Evaluation of
CE
30
ACCEPTED MANUSCRIPT
181. G. Koncsos, Z.V. Varga, T. Baranyai, K. Boengler, S. Rohrbach, L. Li, K.D. Schluter, R.
Schreckenberg, T. Radovits, A. Olah, C. Matyas, A. Lux, M. Al-Khrasani, T. Komlodi, N.
Bukosza, D. Mathe, L. Deres, M. Bartekova, T. Rajtik, A. Adameova, K. Szigeti, P. Hamar,
Z. Helyes, L. Tretter, P. Pacher, B. Merkely, Z. Giricz, R. Schulz, P. Ferdinandy, Diastolic
dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress, American
journal of physiology Heart and circulatory physiology 311 (2016) H927-H943.
182. E.M. Jeong, J. Chung, H. Liu, Y. Go, S. Gladstein, A. Farzaneh-Far, E.D. Lewandowski,
S.C. Dudley, Jr., Role of Mitochondrial Oxidative Stress in Glucose Tolerance, Insulin
Resistance, and Cardiac Diastolic Dysfunction, Journal of the American Heart Association 5
(2016)
183. Y. Kayama, U. Raaz, A. Jagger, M. Adam, I.N. Schellinger, M. Sakamoto, H. Suzuki, K.
Toyama, J.M. Spin, P.S. Tsao, Diabetic Cardiovascular Disease Induced by Oxidative
PT
Stress, Int J Mol Sci 16 (2015) 25234-25263.
184. C.Y. Huang, W.J. Ting, J.Y. Yang, W.T. Lin, Resveratrol attenuated hydrogen peroxide-
induced myocardial apoptosis by autophagic flux, Food & nutrition research 60 (2016)
RI
30511.
185. S. Sciarretta, M. Volpe, J. Sadoshima, NOX4 regulates autophagy during energy
deprivation, Autophagy 10 (2014) 699-701.
SC
186. S. Sciarretta, P. Zhai, D. Shao, D. Zablocki, N. Nagarajan, L.S. Terada, M. Volpe, J.
Sadoshima, Activation of NADPH oxidase 4 in the endoplasmic reticulum promotes
cardiomyocyte autophagy and survival during energy stress through the protein kinase
NU
RNA-activated-like endoplasmic reticulum kinase/eukaryotic initiation factor
2alpha/activating transcription factor 4 pathway, Circ Res 113 (2013) 1253-1264.
187. H. Yuan, C.N. Perry, C. Huang, E. Iwai-Kanai, R.S. Carreira, C.C. Glembotski, R.A.
MA
189. D.A. Kubli, A.B. Gustafsson, Unbreak my heart: targeting mitochondrial autophagy in
diabetic cardiomyopathy, Antioxidants & redox signaling 22 (2015) 1527-1544.
E
190. C. Zhang, T.W. Syed, R. Liu, J. Yu, Role of Endoplasmic Reticulum Stress, Autophagy, and
Inflammation in Cardiovascular Disease, Frontiers in cardiovascular medicine 4 (2017) 29.
PT
191. L.M.D. Delbridge, K.M. Mellor, D.J. Taylor, R.A. Gottlieb, Myocardial stress and
autophagy: mechanisms and potential therapies, Nature reviews Cardiology (2017)
192. P.E. Munasinghe, F. Riu, P. Dixit, M. Edamatsu, P. Saxena, N.S. Hamer, I.F. Galvin, R.W.
CE
31
ACCEPTED MANUSCRIPT
FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice,
Clin Sci (Lond) 130 (2016) 625-641.
197. X. Yuan, Y.C. Xiao, G.P. Zhang, N. Hou, X.Q. Wu, W.L. Chen, J.D. Luo, G.S. Zhang,
Chloroquine improves left ventricle diastolic function in streptozotocin-induced diabetic
mice, Drug Des Devel Ther 10 (2016) 2729-2737.
198. X. Xu, S. Kobayashi, K. Chen, D. Timm, P. Volden, Y. Huang, J. Gulick, Z. Yue, J.
Robbins, P.N. Epstein, Q. Liang, Diminished autophagy limits cardiac injury in mouse
models of type 1 diabetes, J Biol Chem 288 (2013) 18077-18092.
199. L.R. Peterson, P. Herrero, A.R. Coggan, Z. Kisrieva-Ware, I. Saeed, C. Dence, D. Koudelis,
J.B. McGill, M.R. Lyons, E. Novak, V.G. Davila-Roman, A.D. Waggoner, R.J. Gropler,
Type 2 diabetes, obesity, and sex difference affect the fate of glucose in the human heart,
Am J Physiol Heart Circ Physiol 308 (2015) H1510-1516.
PT
200. M.R. Lyons, L.R. Peterson, J.B. McGill, P. Herrero, A.R. Coggan, I.M. Saeed, C. Recklein,
K.B. Schechtman, R.J. Gropler, Impact of sex on the heart's metabolic and functional
responses to diabetic therapies, Am J Physiol Heart Circ Physiol 305 (2013) H1584-1591.
RI
SC
NU
MA
E D
PT
CE
AC
32
ACCEPTED MANUSCRIPT
Figure Legends
Figure 1. Mechanisms of diastolic dysfunction in the diabetic heart. Diabetes is associated with
impaired glucose uptake and utilization, a shift towards fatty acid oxidation and accumulation of
glycogen and lipids. Metabolic dysregulation may trigger energy stress responses such as oxidative
stress and autophagy disturbance linked with increased cell death, fibrosis and ultimately leading to
PT
impaired cardiac relaxation and diastolic dysfunction in diabetes.
RI
SC
Figure 2. Molecular mechanisms of diabetic cardiomyopathy. Diabetes is associated with
increased circulating fatty acids, increased glucose, either insulin deficiency (T1D) or
NU
hyperinsulinemia (T2D) and increased catecholamines from heightened sympathetic activity. These
systemic perturbations lead to increased cardiac fatty acid uptake, impaired glucose uptake and
MA
dysregulated insulin and β-adrenergic signaling. A shift towards fatty acid oxidation and
accumulation of glycogen and lipids are common observations in the diabetic heart and although
D
inconsistent findings have been reported relating to AMPK and autophagic processes, disturbances
E
in these pathways may exacerbate the metabolic mismanagement in the heart. ‘+’, upregulation; ‘-’,
PT
33
ACCEPTED MANUSCRIPT
DIABETES
cardiac metabolic dysregulation:
• impaired glucose uptake & utilization
• shift towards fatty acid oxidation
• accumulation of fuel stores (glycogen and lipids)
PT
Diastolic Dysfunction
RI
Figure 1. Mechanisms of diastolic dysfunction in the diabetic heart. Diabetes is associated with
impaired glucose uptake and utilization, a shift towards fatty acid oxidation and accumulation of
glycogen and lipids. Metabolic dysregulation may trigger energy stress responses such as oxidative
stress and autophagy disturbance linked with increased cell death, fibrosis and ultimately leading to
SC
impaired cardiac relaxation and diastolic dysfunction in diabetes.
NU
MA
E D
PT
CE
AC
34
ACCEPTED MANUSCRIPT
- insulin (T1D)
+ fatty acids + glucose + insulin (T2D) + catecholamines
- IR β1 +/- ?
- IRS1/2 cAMP
fatty acid - glycolysis
+ oxidation acute
glucose
- - PKA
cardiomyocyte
oxidation PI3K/Akt
lipid chronic
+ droplets + glycogen
mTOR Ca2+
regulation
AMPK autophagy
+/- ? +/- ?
PT
and cardiac dysfunction
Figure 2. Molecular mechanisms of diabetic cardiomyopathy. Diabetes is associated with increased circulating fatty
acids, increased glucose, either insulin deficiency (T1D) or hyperinsulinemia (T2D) and increased catecholamines from
heightened sympathetic activity. These systemic perturbations lead to increased cardiac fatty acid uptake, impaired
RI
glucose uptake and dysregulated insulin and β-adrenergic signaling. A shift towards fatty acid oxidation and accumulation
of glycogen and lipids are common observations in the diabetic heart and although inconsistent findings have been
reported relating to AMPK and autophagic processes, disturbances in these pathways may exacerbate the metabolic
SC
mismanagement in the heart. ‘+’, upregulation; ‘-’, downregulation, ‘mTOR’ mammalian target of rapamycin.
NU
MA
E D
PT
CE
AC
35
ACCEPTED MANUSCRIPT
Table 1. Reports of cardiac glycogen content in models of diabetes.
Cardiac glycogen Phenotype
Phenotype Species Model Reference
content duration
nr Human Diabetic Patient Chronic [162]
T1D Rat Alloxan inj Short term [77, 84]
T1D Rat Alloxan inj Chronic [82, 85]
T1D Rat STZ inj Short term [79, 87-89]
[78, 81, 87-89,
T1D Rat STZ inj Chronic
91, 164]
T1D Rat BB Wistar Chronic [86]
T1D Dog Alloxan inj Chronic [83]
↑ T1D Rabbit Alloxan inj nr [90]
PT
T2D Human T2D Patient Chronic [93]
T2D Rat ZDF Chronic [94, 99, 100]
RI
T2D (late) Rat ZDF Chronic [96]
T2D Rat STZ inj (low dose) Chronic [98]
T2D Mouse db/db Chronic [92, 95, 97]
SC
T2D Hamster CHAD strain Chronic [101]
Ins res +
Rat Glucosamine inj Short term [102]
obesity
NU
T1D Rat STZ inj nr [108]
T1D Swine STZ inj Chronic [105]
HFD + STZ inj
T2D Rat Chronic [107]
(mod dose)
MA
Ins res +
Mouse HFD Chronic [103]
obesity
E
Obesity
T1D, type I diabetes; T2D, type II diabetes; ins res, insulin resistance; inj, injection; STZ, streptozotocin;
HFD, high fat diet; ZDF, Zucker diabetic fatty; nr, not recorded. Short term 1 week. Chronic > 1 week.
For genetic models, duration of disease is equivalent to final age. #With 30% sucrose.
36
ACCEPTED MANUSCRIPT
Highlights
Diabetes-related systemic disturbances facilitate alterations in cardiac metabolism.
Dysregulation of cardiac insulin, AMPK and β-adrenergic signaling is well documented.
Diabetes alters cardiac substrate utilization and storage of glucose and lipids.
Cardiac energy stress responses in diabetes (eg. oxidative stress and autophagy) are linked with
cell death.
Molecular disturbances ultimately culminate in impaired relaxation and functional performance
in the diabetic heart.
PT
RI
SC
NU
MA
E D
PT
CE
AC
37